MP0250-a dual inhibitor of VEGF and HGF - plus bortezomib plus dexamethasone in a phase 2 open-label, single-arm, multicenter trial in patients with refractory and relapsed multiple myeloma (RRMM)

被引：0
|
作者：
Raab, M. S. [1 ]
Ria, R. [2 ]
Schlenzka, J. [1 ]
Krahnke, T. [3 ]
Haunschild, J. [4 ]
Herrmann, F. [4 ]
Fiedler, U. [5 ]
Dawson, K. [6 ]
Stumpp, M. T. [7 ]
Mehr, K. Tadjalli [4 ]
Harstrick, A. [4 ]
Vacca, A. [2 ]
Goldschmidt, H. [1 ]
机构：
[1] Heidelberg Univ Hosp, Dept Haematol Oncol & Rheumatol, Heidelberg, Germany
[2] Univ Bari, Med Sch, Dept Biomed Sci & Human Oncol, Sect Internal Med, Bari, Italy
[3] Gogitars GmbH, Biostat, Heidelberg, Germany
[4] Mol Partners AG, Clin Dev, Schlieren, Switzerland
[5] Mol Partners AG, Preclin, Schlieren, Switzerland
[6] Mol Partners AG, Preclin Toxicol, Schlieren, Switzerland
[7] Mol Partners AG, CSO, Schlieren, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1041TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Palumbo, Antonio
    Joshua, Douglas
    Pour, Ludek
    Hajek, Roman
    Facon, Thierry
    Ludwig, Heinz
    Oriol, Albert
    Goldschmidt, Hartmut
    Rosinol, Laura
    Straub, Jan
    Suvorov, Aleksandr
    Araujo, Carla
    Rimashevskaya, Elena
    Pika, Tomas
    Gaidano, Gianluca
    Weisel, Katja
    Goranova-Marinova, Vesselina
    Schwarer, Anthony
    Minuk, Leonard
    Masszi, Tamas
    Karamanesht, Ievgenii
    Offidani, Massimo
    Hungria, Vania
    Spencer, Andrew
    Orlowski, Robert Z.
    Gillenwater, Heidi H.
    Mohamed, Nehal
    Feng, Shibao
    Chng, Wee-Joo
    LANCET ONCOLOGY, 2016, 17 (01): : 27 - 38
  • [42] Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeffrey Lee
    Jakubowiak, Andrzej J.
    Zonder, Jeffrey A.
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur S.
    Bar, Michael H.
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Martin, Thomas
    Laubach, Jacob P.
    Allerton, Jeffrey P.
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    BLOOD, 2011, 118 (21) : 371 - 371
  • [43] Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial
    Ren, Shengxiang
    He, Jianxing
    Fang, Yong
    Chen, Gongyan
    Ma, Zhiyong
    Chen, Jianhua
    Guo, Renhua
    Lin, Xiaoyan
    Yao, Yu
    Wu, Gang
    Wang, Quanren
    Zhou, Caicun
    JTO CLINICAL AND RESEARCH REPORTS, 2022, 3 (05):
  • [44] Pomalidomide, bortezomib, and dexamethasone vs bortezomib and dexamethasone in relapsed or refractory multiple myeloma (OPTIMISMM): final survival outcomes from a randomized, open-label, phase 3 trial
    Beksac, Meral
    Richardson, Paul
    Oriol, Albert
    Lindsay, Jindriska
    Schjesvold, Fredrik
    Galli, Monica
    Yagci, Munci
    Larocca, Alessandra
    Weisel, Katja
    Yu, Xin
    Donahue, Cynthia
    Acosta, Jorge
    Peluso, Teresa
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S27 - S28
  • [45] Elotuzumab plus bortezomib and dexamethasone (EBd) versus bortezomib and dexamethasone (Bd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)-2-year follow-up
    Palumbo, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Lynch, M.
    Jou, Y-M
    Jakubowiak, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 28 - 28
  • [46] A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
    Geng, Chuanying
    Hou, Jian
    Zhao, Yaozhong
    Ke, Xiaoyan
    Wang, Zhao
    Qiu, Lugui
    Xi, Hao
    Wang, Fuxu
    Wei, Na
    Liu, Yan
    Yang, Shifang
    Wei, Peng
    Zheng, Xiangjun
    Huang, Zhongxia
    Zhu, Bing
    Chen, Wen-Ming
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (11) : 1037 - 1042
  • [47] Anlotinib plus oral fluoropyrimidine S1 in treating patients with refractory or relapsed small cell lung cancer (SALTER TRIAL): An open-label, multicenter, single-arm, phase II trial
    Wang, W.
    Lv, D.
    Wu, X.
    Ye, J.
    Zhou, C.
    Wang, J.
    Ling, L.
    Yang, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S1164 - S1164
  • [48] An Open-Label Phase 2 Study of Carfilzomib plus Dexamethasone to Assess Tolerability and Adherence in Patients with Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers
    Fonseca, Rafael
    Alsina, Melissa
    Berdeja, Jesus
    Heitner, Stephen B.
    Morris, Christopher
    Khurana, Monica
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S241
  • [49] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mellqvist, U. H.
    Paba-Prada, C.
    Palumbo, A.
    Plesner, T.
    Sonneveld, P.
    Voorhees, P.
    Byrne, C.
    Harmenberg, J.
    Nordstrom, E.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 375 - 376
  • [50] A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: The Japanese MM-011 trial
    Ichinohe T.
    Kuroda Y.
    Okamoto S.
    Matsue K.
    Iida S.
    Sunami K.
    Komeno T.
    Suzuki K.
    Ando K.
    Taniwaki M.
    Tobinai K.
    Chou T.
    Kaneko H.
    Iwasaki H.
    Uemura C.
    Tamakoshi H.
    Zaki M.H.
    Doerr T.
    Hagiwara S.
    Experimental Hematology & Oncology, 5 (1)
12345